Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
vaccine
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02320305CT.gov MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery | — | Completed | — | — | — |
NCT01307618CT.gov Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT00470015CT.gov Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | — | Completed | — | — | — |
NCT00295958CT.gov LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00091338CT.gov Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00334776CT.gov Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00031733CT.gov Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma | — | Completed | — | — | — |
NCT00025181CT.gov Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | — | Completed | — | — | — |
NCT00037037CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma | — | Unknown | — | — | — |
NCT00010309CT.gov Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | — | Unknown | — | — | — |
Show 8 more trialsShow fewer
NCT00006385CT.gov Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00005841CT.gov Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | — | Terminated | — | — | — |
NCT00019994CT.gov Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00006113CT.gov Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | — | Terminated | — | — | — |
NCT00003792CT.gov Vaccine Therapy in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00019721CT.gov Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00019214CT.gov Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT00002952CT.gov Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Mart-1 Antigen (this asset) | Mayo Clinic | P2 | BB · 70 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Cediranib | Jonsson Comprehensive Cancer Center | P3 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Mart-1 Antigen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Uveal Melanoma | — | P3 | BB · 64 |
| Melanoma | — | P2 | BB · 64 |
| Metastatic Melanoma | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Mart-1 Antigen in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/mart-1-antigen-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →